摘要
目的探讨无锡地区乙型肝炎病毒基因型对阿德福韦酯抗病毒治疗效果的影响。方法选取2010年5月～2012年4月无锡市第五人民医院就诊的148倒慢性乙型肝炎患者。采用实时荧光定量PCR法检测血清HBVDNA，时间分辨荧光免疫检测HBeAg，采用PCR荧光探针法检测HBV基因型。慢性乙型肝炎患者分为两组：B基因型组82例，C基因型组66例，分别给予阿德福韦酯抗病毒治疗。观察用药12，24，48周时HBV—DNA阴转率和HBeAg血清学转换率。结果148例慢性乙型肝炎病毒感染者检出B基因型82例（55．4％），C基因型66例（44．6％），未发现混合型。阿德福韦酯抗病毒治疗12，24周时，B基因型组和C基因型组血清HBVDNA阴转率11．0％，10．6％和34．1％，31．8％，两组差异均无统计学意义（x^2=1．35，2．07，P〉0．05）；治疗48周时B基因型组、C基因型组血清HBVDNA阴转率42．7％和33．3％，差异有统计学意义（x^25．78，P〈O．05）。B基因型与C基因型者血清HBeAg转换率比较差异无统计学意义。结论阿德福韦酯抗病毒治疗慢性乙型肝炎，感染B基因型者治疗效果优于感染C基因型者；血清HBeAg转换率与HBV基因型无明显关系。
Objective To investigate the influence of HBV genotypes on the therapeutic effects of adefovir dipivoxil in chronic hepatitis B patients in Wuxi area. Methods One hundred and fourty-eight CHB patients from May 2010 to April 2012 in Wuxi No. 5 hospital were enrolled into this study,including 82 cases infected with HBV genotype B and 66 cases with geno- type C. HBV viral loads were determined by real-time PCR method. HBeAg were determined by time resolved fluorescence immunoassay. HBV genotypes wereidentified in CHB patients by PCR method. The clinical data in terms of serum HBV DNA seroclearance and HBeAg seroconversion rate were analyzed against their HBV genotypes. Results Genotype B and C were found in 82（55.40/00） and 66（44.6%） cases, respectively. The serum HBV DNA seroclearance in patients with genotype B and C at their treatment times of 12,24 and 48 weeks was 11.0 %, 10.6 %（x^2= 1.35, P〉0.05）, 34.1%, 31.8 % （x^2 =2. 07, P〉0. 05） and 42. 7 %,33.3 % （x^2 = 5. 78, P〈0. 05）. Conclusion Genotype B HBV had a better serum HBV DNA seroclearance response to ADV therapy in chronic hepatitis B patients than that of genotype C.
出处
《现代检验医学杂志》
CAS
2012年第5期54-56,共3页
Journal of Modern Laboratory Medicine
关键词
乙型肝炎病毒
基因型
阿德福韦酯
Keywords.. hepatitis B virus
genotype
adefovir dipivoxil
